YD Bio Ltd (YDES) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
YD Bio Ltd stock (YDES) is currently trading at $7.73. YD Bio Ltd PS ratio (Price-to-Sales) is 896.79. WallStSmart rates YDES as Sell.
- YDES PE ratio analysis and historical PE chart
- YDES PS ratio (Price-to-Sales) history and trend
- YDES intrinsic value — DCF, Graham Number, EPV models
- YDES stock price prediction 2025 2026 2027 2028 2029 2030
- YDES fair value vs current price
- YDES insider transactions and insider buying
- Is YDES undervalued or overvalued?
- YD Bio Ltd financial analysis — revenue, earnings, cash flow
- YDES Piotroski F-Score and Altman Z-Score
- YDES analyst price target and Smart Rating
YD Bio
📊 No data available
Try selecting a different time range
Smart Analysis
YD Bio Ltd (YDES) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
YD Bio Ltd (YDES) Key Strengths (1)
Revenue surging 95.60% year-over-year
YD Bio Ltd (YDES) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 896.8x annual revenue
Very expensive at 75.7x book value
Very low institutional interest at 0.47%
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
YD Bio Ltd (YDES) Detailed Analysis Report
Overall Assessment
This company scores 20/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 1 register as strengths (avg 10.0/10) while 7 fall into concern territory (avg 1.6/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth. Growth metrics are encouraging with Revenue Growth at 95.60%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (896.79), Price/Book (75.68) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -42.70%, Operating Margin at -444.60%, Profit Margin at -276.60%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -42.70% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 95.60% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
YDES Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
YDES's Price-to-Sales ratio of 896.79x sits near its historical average of 1028.74x (14th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 24% below its historical high of 1185.58x set in Mar 2026, and 20% above its historical low of 748.93x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~1185.6x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for YD Bio Ltd (YDES) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
YD Bio Ltd is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 510,360 with 96% growth year-over-year. The company is currently unprofitable, posting a -276.6% profit margin.
Key Findings
Revenue growing at 96% YoY, reaching 510,360. This pace significantly outperforms most BIOTECHNOLOGY peers.
The company is unprofitable with a -276.6% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -298,190, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can YD Bio Ltd maintain 96%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact YD Bio Ltd.
Bottom Line
YD Bio Ltd is a high-conviction growth story with revenue accelerating at 96% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -276.6% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About YD Bio Ltd(YDES)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Breeze Holdings Acquisition Corp. The company is headquartered in Taipei, Taiwan.